529516-61-8

Basic information

• Product Name: (S)-1-BENZYL 4-TERT-BUTYL 2-(HYDROXYMETHYL)PIPERAZINE-1,4-DICARBOXYLATE
• Synonyms: (S)-1-BENZYL 4-TERT-BUTYL 2-(HYDROXYMETHYL)PIPERAZINE-1,4-DICARBOXYLATE
• CAS NO: 529516-61-8
• Molecular Formula: C18H26N2O5
• Molecular Weight: 350.40944
• Mol File: 529516-61-8.mol

Chemical Properties

• Boiling Point: 480.5±30.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: (S)-1-BENZYL 4-TERT-BUTYL 2-(HYDROXYMETHYL)PIPERAZINE-1,4-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-BENZYL 4-TERT-BUTYL 2-(HYDROXYMETHYL)PIPERAZINE-1,4-DICARBOXYLATE(529516-61-8)
• EPA Substance Registry System: (S)-1-BENZYL 4-TERT-BUTYL 2-(HYDROXYMETHYL)PIPERAZINE-1,4-DICARBOXYLATE(529516-61-8)

Safety Data

• Hazardous Substances Data: 529516-61-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-Benzyl 4-tert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate is used as a pharmaceutical compound for its potential to interact with biological targets. Its unique structure allows for the possibility of developing new drugs that can target specific receptors or enzymes in the body, potentially leading to novel treatments for various diseases and conditions.
Used in Drug Development:
In the field of drug development, (S)-1-Benzyl 4-tert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate serves as a starting point for the synthesis of new drug candidates. Its structural features can be modified and optimized to enhance its pharmacological properties, such as potency, selectivity, and bioavailability. This process can lead to the discovery of new drugs with improved efficacy and safety profiles.
Used in Medicinal Chemistry Research:
(S)-1-Benzyl 4-tert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate is utilized as a research tool in medicinal chemistry. Scientists can study its interactions with various biological targets to gain insights into the underlying mechanisms of action and potential therapeutic applications. This knowledge can be applied to design and develop more effective drugs for treating different medical conditions.

Upstream product

• 2762-32-5 piperazine-2-carboxylic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 501-53-1 benzyl chloroformate 
• 314741-40-7 (3S)-3-(hydroxymethyl)-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 
• 278788-66-2 (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate 
• 128019-59-0 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 126937-41-5 1-(benzyloxycarbonyl)-4-(tert-butoxycarbonyl)-2-piperazinecarboxylic acid 
• 126937-42-6 piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester 
• 143540-05-0 2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 301673-16-5 tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate 
• 935544-47-1 tert-butyl 3-oxotetrahydro-1H-oxazolo[3,4-a]pyrazine-7(3H)-carboxylate 
• 100-51-6 benzyl alcohol 
• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 2306248-13-3 tert-butyl (R)-3-(cyanomethyl)piperazine-1-carboxylate 
• 2158302-00-0 1-benzyl 4-(tert-butyl) (R)-2-(cyanomethyl)piperazine-1,4-dicarboxylate 
• 2502156-03-6 (2S,4S)-1-((S)-2-(3-(3-((S)-2-(((7-(8-chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 2502156-03-6 (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

Heterocyclic compound, pharmaceutical composition and application

The invention discloses a heterocyclic compound which is a heterocyclic compound shown as a formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a hydrate, a solvate, a metabolite or a prodrug thereof. The heterocyclic compound can be used for preparing medicines for treating and/or preventing cancers related to KRAS G12C mutation. The invention also discloses a pharmaceutical composition containing the heterocyclic compound, and application of the compound shown in the formula I, or pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, metabolite, prodrug or pharmaceutical composition thereof in preparation of drugs.

TRICYCLIC PYRIDONES AND PYRIMIDONES

A compound of Formula (I) is provided: (I) where the variables are defined herein.

Substituted heteroaromatic ring dihydropyrimidinone derivative as well as preparation method and medical application thereof

The invention discloses a substituted heteroaromatic ring dihydropyrimidinone derivative with selective inhibition effect on KRAS gene mutation or a pharmaceutically acceptable salt, a stereoisomer, asolvate or a prodrug thereof. The substituted heteroaromatic ring dihydropyrimidinone derivative is shown as a formula (I), and each group in the formula is as defined in the specification. In addition, the invention also discloses a pharmaceutical composition containing the compound and application of the compound in preparation of cancer drugs.

RAS INHIBITORS AND METHODS OF USING THE SAME

Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.

Compound for inhibiting KRASG12C mutant protein, preparation method and application thereof

The present invention discloses a compound represented by the following formula (I), and an isomer or a pharmaceutically acceptable salt thereof. The compound can be used for inhibiting KRASG12C mutant protein and treating related cancers.

COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS

Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRas, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The heterobifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS

Therapeutic combinations of hepatitis B virus (HBV) vaccines and capsid assembly modulators (CAMs), such as dihydropyrimidine derivatives are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described.

KRAS G12C INHIBITORS

The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.